0.91 probabilityThe Kaplan-Meier estimate of the probability of being retained in treatment at 12 months was 0.91 in the OSS model.
NigeriaVIH/sidapublished 2025BMC public healthPubMeddocument of 8 observations
Gold tier: mechanically validated evidence, with its primary source.
1,729 evidence items · page 24 / 70
0.91 probabilityThe Kaplan-Meier estimate of the probability of being retained in treatment at 12 months was 0.91 in the OSS model.
NigeriaVIH/sidapublished 2025BMC public healthPubMeddocument of 8 observations
15.5 %A weighted HIV prevalence of 15.5% was found among female sex workers in Nigeria.
NigeriaVIH/sidaobserved 2020published 2025Sexually transmitted infectionsPubMeddocument of 12 observations
16.3 %The prevalence of depression among people living with HIV in two rural secondary health facilities providing antiretroviral therapy services in Southwestern Nigeria was 16.3% between September and December 2020.
Nigeriadépression · VIH/sidaobserved September and December 2020published 2023AIDS research and therapyPubMeddocument of 8 observations
2,000 NGNThe median maximum amount people living with HIV (PLHIV) on antiretroviral therapy (ART) were willing to pay for premium ART services was NGN2,000 (USD $5.56), with an interquartile range of NGN1,000–NGN3,000.
NigeriaVIH/sidaobserved July and August 2019published 2023PloS onePubMeddocument of 9 observations
1,250 sexual_contacts1,250 sexual contacts were elicited using the elicitation box model.
NigeriaVIH/sidaobserved Between March 2021 and April 2022published 2024Global health, science and practicePubMeddocument of 8 observations
53.9 %The prevalence of any ocular disorder among persons living with HIV/AIDS in Osun State, Nigeria was 53.9%.
NigeriaVIH/sidapublished 2026BMC ophthalmologyPubMeddocument of 9 observations
87.5 %87.5% of female sex workers in Kano State, Nigeria, cited desire to know and confirm HIV status as the primary driver for willingness to use HIV services.
NigeriaVIH/sidaobserved 2023published 2025PloS onePubMeddocument of 7 observations
54.4 %Among HIV-positive pregnant women in Kaduna State, 54.4% had a fair knowledge of antiretroviral therapy.
NigeriaVIH/sidapublished 2025Scientific reportsPubMeddocument of 4 observations
67.3 %The majority of the respondents reported a low level of viral load (67.3%).
NigeriaVIH/sidapublished 2024The Nigerian postgraduate medical journalPubMeddocument of 4 observations
1.28 aORMales among young adults living with HIV in Nigeria were more likely to not be retained in care, with an adjusted odds ratio of 1.28.
NigeriaVIH/sidapublished 2020BMJ global healthPubMeddocument of 7 observations
34.3 %Seventy-nine (34.3%) patients among the 230 participants were living with HIV.
NigeriaVIH/sidapublished 2025West African journal of medicinePubMeddocument of 7 observations
Pre-exposure prophylaxis (PrEP) effectively prevents HIV.
NigeriaVIH/sidapublished 2026AIDS and behaviorPubMeddocument of 6 observations
16 %Among 50 HBsAg-positive samples, 16.0% (8/50) had detectable HDV RNA.
NigeriaHepatitis D · VIH/sidaobserved June 2017 to August 2017published 2021Virology journalPubMeddocument of 6 observations
28.3 %Among young key populations aged 15–24 years in Nigeria, the most cited barriers to pre-exposure prophylaxis (PrEP) uptake were lack of access (28.3%) and fear of side effects (28.3%) among female sex workers.
NigeriaVIH/sidaobserved 2020published 2024International journal of STD & AIDSPubMeddocument of 5 observations
30 %Mother-to-child transmission accounts for approximately 30% of the global burden of new paediatric HIV infections.
NigeriaVIH/sidapublished 2024BMC pregnancy and childbirthPubMeddocument of 8 observations
2.98 aORTertiary education was associated with higher odds of prenatal HIV testing among female sex workers in Nigeria (adjusted odds ratio = 2.98).
NigeriaVIH/sidapublished 2024International journal of STD & AIDSPubMeddocument of 12 observations
94.2 %Virologic suppression using a cut-off of less than 400 copies/ml was 94.2% among persons with HIV who initiated ART between January 2016 and September 2022 in Nigeria.
NigeriaVIH/sidapublished 2023AIDS (London, England)PubMeddocument of 4 observations
88.1 %The 6-month retention rate for people living with HIV who accepted the alternative treatment method was 88.1% (n=332).
NigeriaVIH/sidaobserved 6-monthpublished 2019International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument of 6 observations
1.64 AORLiving with HIV was associated with increased odds of anxiety related to COVID-19 (adjusted odds ratio: 1.64).
NigeriaCOVID-19 · VIH/sidaobserved 2020published 2022Frontiers in public healthPubMeddocument of 10 observations
2.53 per_1000_person-yearsThe incidence of Kaposi Sarcoma decreased from 2.53 to 1.58 per 1,000 person-years from 2006 to 2009 to 2010–2016.
Nigeriasarcome de Kaposi · VIH/sidaobserved 2006 to 2009published 2023BMC cancerPubMeddocument of 2 observations
Neither viral load nor blood CD4+ cell count was significantly different between all HbAS versus all HbAA patients.
NigeriaVIH/sidapublished 2022The open AIDS journaleurope_pmcdocument of 3 observations
7.1 %7.1% of the eligible entries received a score of 3 for desirability.
NigeriaVIH/sidaobserved October 2018 to June 2019published 2020PloS onePubMeddocument of 10 observations
78 %Among Test and Treat patients with a documented viral load, 78% were suppressed (≤400 copies/ml) at 12 months.
NigeriaVIH/sidapublished 2019PloS onePubMeddocument of 7 observations
90 %The self-reported ART adherence level was 90.0% in the north-east of Nigeria.
NigeriaVIH/sidapublished 2022African journal of AIDS research : AJARPubMeddocument of 4 observations
6.3 %Minor PI resistance-associated mutation N88D was identified in 6.3% of CRF02_AG HIV-1 isolates.
NigeriaVIH/sidapublished 2020PloS onePubMeddocument of 11 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.